127684-87-1

Upstream product

• 4799-68-2 3-benzyloxypropan-1-ol 
• 50-00-0 formaldehyd 

Downstream Products

• 205943-54-0 (1S,2R,6S)-2-(3-Benzyloxy-propoxymethoxymethyl)-6-{[((R)-2-hydroxymethyl-3,3-dimethyl-butyl)-methyl-amino]-methyl}-4,4-dimethyl-cyclohexanol 
• 356785-82-5 2-[(3-benzyloxy-propoxymethyl)-ethoxy-phosphinoylmethyl]-acrylic acid methyl ester 
• 356785-81-4 (3-benzyloxy-propoxymethyl)-phosphinic acid ethyl ester 
• 356785-80-3 (3-benzyloxy-propoxymethyl)-(1,1-diethoxy-ethyl)-phosphinic acid ethyl ester 
• 205943-61-9 (1R,2R,6S)-2-(3-Benzyloxy-propoxymethoxymethyl)-6-({[(R)-2-(tert-butyl-dimethyl-silanyloxymethyl)-3,3-dimethyl-butyl]-methyl-amino}-methyl)-4,4-dimethyl-cyclohexanol 

Relevant academic research and scientific papers

Inhibitors of the bacterial cell wall biosynthesis enzyme MurC

A series of phosphinate transition-state analogues of the L-alanine adding enzyme (MurC) of bacterial peptidoglycan biosynthesis was prepared and tested as inhibitors of the Escherichia coli enzyme. Compound 4 was identified as a potent inhibitor of MurC

AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS

The present invention relates to compounds for stabilising the native tetrameric form of transthyretin and protecting it from proteolytic cleavage; compounds for use in the prevention and treatment of transthyretin amyloidosis; and agents and medicaments comprising such compounds. The compounds are based on a general structure A-L-B, wherein A is a group of formula (II) or of formula (III): or of formula (IV) or of formula (V) B is a group of formula (III), (IV), or (V), or a group of formula (VI) or a group of formula –R10Z, wherein: Z is selected from -CO2R', -CONR'R'', -SO2R' wherein R' and R'' are independently H or C1-C4 alkyl; and R10 is a C1-C4 alkylene or alkenylene group; and L represents a linker group which is a saturated or unsaturated chain of 5 to 13 carbon atoms.